vimarsana.com

Page 199 - Page Interactive Data File News Today : Breaking News, Live Updates & Top Stories | Vimarsana

THESEUS PHARMACEUTICALS, INC : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)

Item 2.02 Results of Operations and Financial Condition. On May 11, 2023, Theseus Pharmaceuticals, Inc. issued a press release announcing the Company s financial results for the quarter ended. | May 11, 2023

Securities exchangeTheseus pharmaceuticals incSecurities exchange actSecurities actExchange actPage interactive data fileEdgar onlineTheseus pharmaceuticalsNc stock exchangePress releaseUarter thrx us88369m1018

ImmunityBio : BLA Update - Form 8-K | MarketScreener

ibrx-20230509 UNITED STATES SECURITIES AND. | May 11, 2023

United statesSan diegoDavidc sachsImmunitybio incJohn hopkins courtSecurities exchangeBusiness development updatesDrug administrationExchange commissionCompany annual report on formSecurities exchange actGeneral instructionSecurities actExchange actBiologics license applicationBacillus calmette gu

ATAI LIFE SCIENCES N V : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)

Item 2.02. Results of Operations and Financial Condition. On May 11, 2023, ATAI Life Sciences N.V. issued a press release announcing its financial results for the quarter ended March 31, 2023. | May 11, 2023

Securities exchangeLife sciencesExchange commission as exhibitExchange commissionCurrent reportSecurities exchange actSecurities actExchange actPress releasePage interactive data fileEdgar onlineAtai life sciencesnv stock exchangePress releaseArch atai nl0015000dx5

CHEMOMAB THERAPEUTICS LTD : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)

Item 2.02. Results of Operations and Financial Condition. On May 11, 2023, Chemomab Therapeutics Ltd. issued a press release announcing its financial results for its first quarter ended March. | May 11, 2023

Chemomab therapeutics ltdSecurities exchangeSecurities exchange actSecurities actExchange actExhibit descriptionPage interactive data fileEdgar onlineChemomab therapeutics ltd stock exchangePress releaseNded cmmb us16385c1045

DBV TECHNOLOGIES S A : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

Item 7.01 Regulation FD Disclosure On May 10, 2023, DBV Technologies S.A. issued a press release entitled DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE. | May 11, 2023

Securities exchangeAnnounces new england journalMedicine publicationData evaluating viaskinCurrent reportSecurities exchange actSecurities actExchange actPage interactive data fileEdgar onlineDbv technologies stock exchangePress releaseHase dbv fr0010417345

vimarsana © 2020. All Rights Reserved.